<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Treatment of dyslipidaemias.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Finnish Medical Society Duodecim. Treatment of dyslipidaemias. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp; Sons; 2010 Aug 3&amp;nbsp;[Various]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates previous versions:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Finnish Medical Society Duodecim. Treatment of hyperlipidaemia: aims and selection. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp;amp; Sons; 2007 Feb 9 [Various].&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Finnish Medical Society Duodecim. Drug treatment for hyperlipidaemias. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp;amp; Sons; 2008 Jan 3 [Various]. [3 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Atherosclerosis of native arteries of the extremities, unspecified  (440.20); Atherosclerosis of other specified arteries  (440.8); Diabetes with other coma, type I [juvenile type], not stated as uncontrolled  (250.31); Diabetes with other coma, type II or unspecified type, not stated as uncontrolled  (250.30); Loss of weight  (783.21); Unspecified acquired hypothyroidism  (244.9); Unspecified cerebrovascular disease  (437.9); Unspecified disorder of lipoid metabolism  (272.9)"/><FieldValue Value="MSH: Allylamine ; Anion Exchange Resins ; Anticholesteremic Agents ; Atherosclerosis ; Azetidines ; Bezafibrate ; Blood Chemical Analysis ; Cerebrovascular Disorders ; Cholestyramine Resin ; Clofibric Acid ; Colestipol ; Diabetes Mellitus ; Diagnosis, Differential ; Diet, Fat-Restricted ; Dyslipidemias ; Exercise ; Fatty Acids, Monounsaturated ; Fenofibrate ; Fish Oils ; Fluorobenzenes ; Galactans ; Gemfibrozil ; Heptanoic Acids ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypercholesterolemia ; Hyperlipidemias ; Hyperlipoproteinemia Type II ; Hypertriglyceridemia ; Hypothyroidism ; Indoles ; Life Style ; Lipid Metabolism Disorders ; Lovastatin ; Mannans ; Medical History Taking ; Myalgia ; Myocardial Ischemia ; Nicotinic Acids ; Plant Gums ; Pravastatin ; Pyrimidines ; Pyrroles ; Referral and Consultation ; Risk Assessment ; Simvastatin ; Smoking Cessation ; Sulfonamides ; Thyroxine ; Weight Loss "/><FieldValue Value="MTH: Alanine aminotransferase measurement ; Antilipemic agent ; Atherosclerosis ; Azetidines ; Blood Chemical Analysis ; Body Weight decreased ; Cerebrovascular Disorders ; Cessation of smoking ; Creatine kinase measurement ; Diabetes Mellitus ; Differential Diagnosis ; Exercise ; Fat-Restricted Diet ; Fenofibrate ; Fish Oils ; follow-up ; Follow-up status ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypercholesterolemia ; Hypercholesterolemia, Familial ; Hyperlipidemia ; Hypertriglyceridemia ; Indoles ; Life Style ; Lipid Metabolism Disorders ; Lovastatin ; Measurement of serum lipid level ; Myalgia ; Myocardial Ischemia ; Nicotinic Acids ; Pyrimidines ; Pyrroles ; Risk Assessment ; Sulfonamides ; Thyroxine "/><FieldValue Value="PDQ: atorvastatin ; fenofibrate ; hypothyroidism ; lovastatin ; pravastatin ; simvastatin ; thyroxine "/><FieldValue Value="SNOMEDCT_US: Alanine aminotransferase measurement  (34608000); Anion exchange resin  (346322006); Anion exchange resin  (372604009); Antilipemic agent  (373267003); Antilipemic agent  (57952007); Assessment for risk of cardiovascular disease  (441829007); Atherosclerosis  (38716007); Atorvastatin  (108600003); Atorvastatin  (373444002); Bezafibrate  (319937007); Bezafibrate  (396025003); Blood chemistry  (166312007); Cerebrovascular disease  (62914000); Cholestyramine resin  (387408001); Cholestyramine resin  (72824008); Clinical chemistry analyzer  (11987000); Colesevelam  (441851004); Colesevelam  (442510005); Colestipol  (372811005); Colestipol  (66971004); Creatine kinase measurement  (397798009); Diabetes mellitus  (73211009); Differential diagnosis  (47965005); Disorder of lipid metabolism  (267431006); Dyslipidemia  (370992007); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Ezetimibe  (408041006); Ezetimibe  (409149001); Familial hypercholesterolemia  (190773008); Familial hypercholesterolemia  (398036000); Fasting lipid profile  (252150008); Fenofibrate  (108603001); Fenofibrate  (386879008); Fish oils  (346441008); Fluvastatin  (387585004); Fluvastatin  (96307003); Follow-up status  (308273005); Gemfibrozil  (35282000); Gemfibrozil  (387189002); Guar gum  (325281002); Guar gum  (395734009); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hypercholesterolemia  (13644009); Hyperlipidemia  (55822004); Hypertriglyceridemia  (302870006); Hypothyroidism  (40930008); Life style  (134436002); Life style  (60134006); Lovastatin  (386024001); Lovastatin  (96303004); Low fat diet  (16208003); Low fat diet  (436861000124104); Measurement of serum lipid level  (271244005); Mixed hypercholesterolemia and hypertriglyceridemia  (129591001); Monounsaturated fatty acid  (102718001); Muscle pain  (68962001); Myocardial ischemia  (414545008); Myocardial ischemia  (414795007); Pravastatin  (373566006); Pravastatin  (96305006); Pyrimidine  (7321000); Pyrrole  (115667008); Risk assessment  (225338004); Rosuvastatin  (406436002); Rosuvastatin  (700067006); Secondary hyperlipidemia  (402727002); Simvastatin  (387584000); Simvastatin  (96304005); Thyroxine  (38076006); Thyroxine  (73187006); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005)"/><FieldValue Value="UMD: Analyzers, Laboratory, Clinical Chemistry  (15-551)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Dyslipidemias&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Hypercholesterolemia alone (including familial hypercholesterolemia) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Increased plasma triglycerides and cholesterol &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pure hypertriglyceridemia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dyslipidemia secondary to hypothyroidism &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Atherosclerotic arterial disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Evaluation" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Health Care Providers" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with ischemic heart disease, other atherosclerotic diseases (cerebrovascular disease, peripheral arterial disease) or diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptomless individuals with or at high risk for dyslipidemia &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation/Risk Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Determination of age and living habits &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of risk for arterial disease based on standard risk calculators &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ruling out secondary hypercholesterolemia &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle changes including smoking cessation, weight reduction, increased physical activity, reduced intake of saturated and trans fats &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antihyperlipidemic agents&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Resins (cholestyramine, colesevelam) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fibrates (bezafibrate, fenofibrate, and gemfibrozil) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ezetimibe &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nicotinic acid &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fish oils &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thyroxine replacement therapy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lipid levels &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Safety tests: serum alanine aminotransferase (ALT) concentration and creatine kinase in patients with myalgia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Referral for specialist consultation &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reduction in lipid levels &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of myocardial infarction, need for coronary surgery and mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of myopathy and other side effects &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classification of the Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Grading the Quality of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Code&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;High&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very unlikely to change confidence in the estimate of effect.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Several high-quality studies with consistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;In special cases: one large, high-quality multi-centre trial &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One high-quality study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Several studies with some limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Very Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Any estimate of effect is very uncertain.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;No direct research evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with very severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group (modified by the EBM Guidelines Editorial Team).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence [A-D] supporting the recommendations are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Essentials&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Goals&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Preventing the progress of arterial disease in those already affected (the most important patient group to be treated) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Decreasing the risk of atherosclerotic arterial disease guided by the total risk (combined effect of risk factors). The assessment of the risk for arterial disease may be facilitated by the use of different risk calculators (e.g., Systematic Coronary Risk Evaluation [SCORE]).&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Note that SCORE only gives the probability of death; the overall risk of arterial disease is significantly higher. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Changing living habits is the primary target in all patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rule out secondary hypercholesterolaemia before starting drug treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The general aim of treatment is to maintain (&quot;5&amp;ndash;4&amp;ndash;3&amp;ndash;2&amp;ndash;1 rule&quot;)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Plasma cholesterol under 5.0 mmol/l (under 4.0 mmol/l in high-risk individuals, if possible) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Plasma low-density lipoprotein (LDL) cholesterol under 3.0 mmol/l (in high-risk individuals under 2.0 mmol/l, if possible). For calculation, see LDL calculator program in the original guideline document. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Plasma high-density lipoprotein (HDL) cholesterol over 1.0 mmol/l &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Plasma triglycerides under 2.0 mmol/l &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Plasma cholesterol/HDL cholesterol ratio under 4.0. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The treatment of a low HDL cholesterol concentration and a high serum triglyceride concentration in association with hypercholesterolaemia is probably beneficial at least in patients with type 2 diabetes. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In hypertriglyceridaemia, the serum triglyceride concentration should be under 10 mmol/l to minimize the risk of pancreatitis. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment in Different Patient Groups&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patients with Ischaemic Heart Disease, Other Atherosclerotic Diseases (Cerebrovascular Disease, Peripheral Arterial Disease) or Diabetes&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The risk of myocardial infarction or cardiac death increases sharply with rising serum cholesterol concentrations in patients with an arterial disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The effectiveness of drug treatment has been clearly shown in controlled studies (Scandinavian Simvastatin Survival Study Group, 1994) &lt;strong&gt;[A]&lt;/strong&gt;. The target plasma cholesterol concentration is under 4.0 mmol/l (LDL cholesterol under 2.0 mmol/l); see table 1 below. There is evidence that especially patients with coronary heart disease or with diabetes benefit from intensive lowering of plasma LDL concentrations (well under 2 mmol/l) (Cannon et al., 2004). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 1. Dyslipidaemia in Patients with Arterial Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 1. Dyslipidaemia in Patients with Arterial Disease&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Plasma Cholesterol (mmol/l)&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;LDL Cholesterol (mmol/l)&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Risk of Disease Progression&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Action&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4.0-4.5 or higher&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2.0-2.5 or higher&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Greatly increased&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Improve diet, change living habits, control cholesterol levels in 1-2 months. Reduce risk by modifying other risk factors. Drug therapy is usually always indicated if target levels are not reached.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Symptomless Individuals&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The general target plasma cholesterol concentration is under 5.0 mmol/l (LDL cholesterol under 3.0 mmol/l). When considering indications for intervention the overall risk is taken into account (age, sex, smoking, blood pressure). Family history as well as HDL and triglyceride concentrations also reflect the risk (working age population is the most important group.) See table 2 below. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In high-risk symptomless individuals the target for plasma cholesterol is under 4.0 mmol/l (LDL cholesterol under 2.0 mmol/l) if possible. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 2. Dyslipidaemia in Asymptomatic Individuals (overall assessment is crucial in planning the treatment)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 2. Dyslipidaemia in Asymptomatic Individuals &quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Plasma Cholesterol (mmol/l)&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;LDL Cholesterol (mmol/l)&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Risk of Disease Progression&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Action&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;8.0 or higher&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;6.5 or higher&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Significantly increased&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess risk factors. Improve diet and change living habits. Control cholesterol levels in 1&amp;ndash;2 months. Drug therapy is usually indicated if lifestyle changes are not sufficient. The probability of an inherited disorder is high. Relatives should be investigated.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;6.5-7.9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5.0-6.4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderately increased&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess risk factors and start dietary therapy. Control treatment effect in 2&amp;ndash;4 months. Further measures (drug treatment) according to outcome of dietary therapy and other risk factors. Hereditary disorders of lipid metabolism are possible (and should be treated in the same way as patients with serum cholesterol above 8 mmol/l).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5.0-6.4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3.0-4.9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Slightly increased&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Counselling on healthy diet and assessment of risk factors. Short-term measures according to other risk factors. Control of plasma cholesterol after 5 years at the latest.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patients over 80 Years of Age&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Treatment started at a younger age is continued. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There are no randomised prognostic studies on treatment started in this age group. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The biological age and the general prognosis are individually taken into account when deciding on treatment, especially in those with arterial disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The principles of treatment are the same as in younger patients. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment of Dyslipidaemia by Lifestyle Changes&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Smoking cessation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weight reduction if needed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Increase of physical activity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduced intake of saturated fat (animal and dairy fat) and trans fats &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Increased intake of polyunsaturated fats and monoenes (vegetable fats) instead of saturated fats (Clarke et al., 1997; Gardner &amp;amp; Kraemer, 1995) &lt;strong&gt;[A]&lt;/strong&gt;. Rapeseed oil is to be recommended. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduced intake of cholesterol &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Increased intake of dietary fibre (Brown et al., 1999; Olson et al., 1997) &lt;strong&gt;[A]&lt;/strong&gt; (gel-forming fibre can be added if indicated) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stanol/sterol margarine can be used (overweight individuals should use diet margarine [40% fat] or nothing). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If target serum lipid values are not reached with diet therapy, start drug treatment (instead of just ordering further control measurements). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Dietary Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The main principles of a &quot;heart-friendly&quot; diet have remained the same for decades and there is no essential new information that would affect them. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fat &amp;lt;30 E% of total energy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Saturated &amp;lt;10 E% &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monoenes and polyunsaturated 20 E% &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dietary cholesterol 250&amp;ndash;300 mg/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Products containing plenty of soluble fibre (Brown et al., 1999; Olson et al., 1997) &lt;strong&gt;[A]&lt;/strong&gt; instead of white carbohydrates (refined sugar, refined flour)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&amp;gt;20 g/1000 kcal (wholemeal bakery products, 500 g of vegetables and fruits per day) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fish twice a week &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoidance of boiled coffee &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction of alcohol consumption if the patient has&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Overweight &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;High blood pressure &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hypertriglyceridaemia &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction of salt intake especially if the patient has high blood pressure. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Expected Effectiveness of Diet Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The effectiveness of diet in the prevention of arterial diseases depends on its individual effect on plasma lipid concentrations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fasting serum cholesterol may decrease by 15% in some patients, but on the average the effect is only 3&amp;ndash;6% (Tang et al., 1998) &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In some individuals the decrease in cholesterol level may exceed 30%. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diet Therapy in Practice&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A thorough diet history, preferably by diary, is the basis of diet counselling. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduce animal and dairy fat. Advise the patient to&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Use fat-free milk or sour milk &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Prefer other low fat milk products &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use vegetable margarine, diet margarine, or plant stanol/sterol margarine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Prefer low fat meat products, fish, skinless poultry, and sausages low in fat. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoid foods rich in cholesterol.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Meat products rich in fat and milk fat &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Internal organs &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Egg yolk &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hidden fats are often saturated.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Pizza &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fast food &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pastries &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduce overweight by hypocaloric diet (or very-low-calorie diet, if necessary) and exercise. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Increase the intake of vegetable fibre (Brown et al., 1999; Olson et al., 1997) &lt;strong&gt;[A]&lt;/strong&gt;. Prefer:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Vegetables, roots, leguminous plants &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Berries and fruit &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Whole-grain cereals. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prepare food without adding fat or by using vegetable oils or vegetable margarines. Suitable oils include canola (most favourable content of fatty acids), olive, sunflower, soy, and maize oil. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use filtered coffee instead of boiled. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As the proportion of fat as energy source is reduced it is substituted by carbohydrates: potatoes, cereals, rice, pasta, fruit, berries, vegetables and roots. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The Effect of Plant Stanol/Sterol Margarine on Cholesterol Concentrations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A daily 25 g dose of sitostanol margarine or 20&amp;ndash;25 g of plant sterol margarine (2 g of sterol) decreases serum cholesterol by 10% and LDL cholesterol by 15% more than ordinary margarine. The concentrations of HDL cholesterol and triglycerides remain unchanged. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Plant stanol/sterol margarine may be suitable as the only treatment for mild hypercholesterolaemia in addition to other diet therapy. Patients that remain hypercholesterolaemic can be treated with a combination of sitostanol and statins. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Some patients with familial and other hypercholesterolaemia may be able to avoid hypocholesterolaemic drugs or reduce their doses by using plant stanol/sterol margarine. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Overweight persons should use low fat modifications where plant stanols/sterols are added. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitor the outcome and weight of the patient. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Drug Treatment for Dyslipidaemias&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Principles&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Make sure that an effective diet has been implemented, and start drug therapy without delay, if clearly indicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;People with arterial disease or diabetes are important target groups. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determine plasma cholesterol, triglycerides, HDL cholesterol and LDL cholesterol before commencing drug treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rule out secondary hypercholesterolaemia. If the cause of secondary hypercholesterolaemia cannot be managed treat the patient as if he had primary hypercholesterolaemia. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Identify patients with familial hypercholesterolaemia (plasma cholesterol usually above 8 mmol/L but may even be lower, xanthomas, family history) in order to screen family members. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Of the most commonly used drugs, statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin), cholestyramine, fibrates (bezafibrate, fenofibrate, gemfibrozil) as well as ezetimibe in combination with simvastatin have been tested in long-term randomized clinical trials based on significant clinical endpoints. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A statin is the drug of choice (Baigent et al., 2005; Dale et al., 2006; Costa et al., 2006; Prospective Studies Collaboration et al., 2007) &lt;strong&gt;[A]&lt;/strong&gt; unless the main abnormality is hypertriglyceridaemia or a low HDL cholesterol concentration. In these cases, even a fibrate may be considered. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If necessary, a statin can be combined with ezetimibe (which in selected cases can also be used as monotherapy). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nicotinic acid may be combined with a statin if affecting HDL cholesterol concentration is a target. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resins and guar gum are used as sole therapy in exceptional cases only. Because they are not absorbed from the intestine they are safe (e.g., during pregnancy and in children). Their adverse effects may cause problems. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Choice of Drug According to the Type of Dyslipidaemia&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;See Table 3 below &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 3. Selection of Lipid Lowering Drug According to the Type of Dyslipidaemia&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 3. Selection of Lipid Lowering Drug According to the Type of Dyslipidaemia&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Dyslipidaemic (pheno)type&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Drug of Choice&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Hypercholesterolaemia alone (familial hypercholesterolaemia)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Statin or a combination of a statin and ezetimibe or a combination of a statin and a resin (the dose of resin &amp;lt;20 g to avoid adverse effects).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Both plasma cholesterol and triglycerides increased&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Statin if plasma triglycerides &amp;lt;4.5 mmol/L.&lt;br /&gt;&#xD;&#xA;            Fibrate + statin if increasing the dose of statin is not sufficient (the need for combination treatment should be evaluated by a specialist) or nicotinic acid + statin especially if HDL cholesterol concentration is small.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Pure hypertriglyceridaemia&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Reducing weight and limiting alcohol consumption is essential before drug treatment is considered. Control of diabetes should be improved. Fibrate. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Hypothyroidism&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Thyroxine substitution normalizes the lipid abnormality if it is caused by hypothyroidism.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Statins (Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In practice the most important group of antilipidaemic agents (Bucher, Griffith, &amp;amp; Guyatt, 1999; Ross et al., 1999) &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mechanism of Action&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Based on the inhibition of the hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase resulting in the inhibition of cholesterol synthesis in hepatocytes. The number of LDL receptors on hepatocytes is increased, and the elimination of LDL from the blood is enhanced. Part of the action may be through very low-density lipoprotein (VLDL) or even other mechanisms. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Effectiveness&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;LDL is decreased by 30% to 40%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;HDL is increased by 5% to 15%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Triglycerides are decreased by 10% to 30% or even more. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combining statins with ezetimibe or resins (Schectman &amp;amp; Hiatt, 1996) &lt;strong&gt;[C]&lt;/strong&gt; results in additive effects. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adverse Effects&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Statins are usually well tolerated, even by elderly patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum aminotransferase concentrations rise in about 2% of the patients. The clinical significance of this is unclear because the patients often have other concomitant factors that may increase the transaminase concentrations. There is no conclusive evidence that statin therapy would cause significant liver damage. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Muscle pains are the clinically most significant adverse effects. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Muscular symptoms are not necessarily caused by statins because such symptoms are also otherwise common in the age groups involved. It is, however, important to find out the cause of the muscular symptom because it may lead to unnecessary cessation of statin therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The incidence of significant muscular adverse effects is &amp;lt;0.1%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum creatine kinase need not be determined routinely. The test is indicated if the patient has unexplained myalgias or muscular symptoms (concentrations 10 times above the upper limit of the reference range are significant). However, statin-induced muscular symptoms are possible even without an increase in the creatine kinase (CK) concentration. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Factors apparently predisposing to myopathy include:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Concurrent use of agents increasing the concentration of statins (e.g., cyclosporine, fibrate, macrolide, or azole medication) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Predisposition, which can be investigated by gene testing &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Very high age &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Multiple concomitant diseases &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Operations &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hypothyroidism &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Vitamin D deficiency &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Individual cases of other adverse effects (e.g., polyneuropathy) have been described in connection with statin treatment but true association has not been verified. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Dosage&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adjust the dose (Illingworth &amp;amp; Tobert, 1994; Hsu, Spinler, &amp;amp; Johnson, 1995) &lt;strong&gt;[A]&lt;/strong&gt; according to response. Doubling the dose provides a further decrease of serum cholesterol by 7%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Atorvastatin: 10 to 80 mg/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fluvastatin: (20) to 40 to 80 mg/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lovastatin: 20 to 80 mg/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pravastatin: 20 to 40 mg/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Simvastatin: 10 to 80 mg/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rosuvastatin: 10 to 40 mg/day &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Resins (Cholestyramine, Colesevelam)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mechanism of Action&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The resins absorb bile acids in the intestine, prevent their reabsorption, and increase their excretion in the faeces. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;They do not increase the excretion of neutral steroids or cause fat malabsorption. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The enhanced excretion of bile acids results in increased metabolism of cholesterol into bile acids and further in an increase in the number of LDL receptors and intake of LDL cholesterol into hepatocytes. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Effectiveness&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Total and LDL cholesterol concentrations decrease by 15% to 30%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Plasma triglyceride concentration may increase. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Dosage&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cholestyramine 16 to 32 g/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Colesevelam 625 mg tablets 4 to 6/day &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adverse Effects&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bowel symptoms: constipation, flatulence, nausea, epigastric pain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Deficiency of fat-soluble vitamins and folic acid because their absorption is impaired &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Interactions&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The absorption of the following drugs may be affected (these drugs should be taken at least 1 hour before or 4 hours after the resin):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Digoxin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thyroxine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Warfarin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thiazide diuretics &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Fibrates (Bezafibrate, Fenofibrate, and Gemfibrozil)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mechanism of Action&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Fibrates act through the nuclear peroxisome proliferator-activated receptor (PPAR) system; the activity of lipoprotein lipase is increased in fat and muscular tissues and the elimination of triglyceride-containing lipoproteins is enhanced. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Effectiveness&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Triglyceride concentration is decreased by 20% to 70%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;HDL cholesterol concentration is increased by 10% to 25%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;LDL cholesterol concentration is decreased if the initial concentration was high. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adverse Effects&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Mild abdominal and bowel irritation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Myalgia and an increase in serum creatine kinase concentration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Possible formation of gallstones &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Increase in serum transaminase levels &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fluid retention, gynaecomastia, and impotence are rare. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Interactions&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Protein-bound drugs are released and their concentrations are increased (warfarin, sulphonylureas). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fenofibrate is the recommended choice in combination with statin therapy. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Contraindications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Severe renal or hepatic insufficiency, diseases of the gallbladder &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Dosage&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bezafibrate: 400 mg x 1 at lunch &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fenofibrate: 200 mg x 1 with meal &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gemfibrozil: 600 to 1200 mg/day divided into 2 to 3 doses &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ezetimibe&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;For patients with hypercholesterolemia in whom statins are contraindicated or to be combined with a statin when the effect of statins alone is insufficient. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mechanism of Action&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prevents cholesterol from being absorbed in the small intestine. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The effect is additive to statins which prevent cholesterol synthesis. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Effectiveness&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;When used alone diminishes the concentration of LDL cholesterol by 18% to 19 %, triglycerides by 4% to 11% and increases the concentration of HDL cholesterol by 2% to 3%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combining ezetimibe with a low dose of statin is additive and equals to a large dose of statin alone in reducing cholesterol concentrations. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Dosage&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;10 mg/day &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adverse Effects&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The studies conducted so far show little adverse effects. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Nicotinic Acid&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Can usually be used in combination with a statin if triglyceride concentration is not sufficiently decreased or if the aim is to increase HDL cholesterol concentration. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Effectiveness&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Nicotinic acid (2 g/day) increases HDL cholesterol concentration by 20% to 28% and decreases LDL cholesterol concentration by 15% to 20% and triglycerides by 20% to 30%. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Dosage&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Gradually increased up to 1&amp;ndash;2 g per day &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Adverse Effects&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Frequently flushing and feeling of heat. These adverse effects are less frequent when a slow-release drug form is used. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combination of the prostaglandin D receptor antagonist laropiprant to nicotinic acid reduces the adverse effects. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May increase blood glucose concentrations. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Fish Oils&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Fish oils (long-chain n-3-fatty acids) 2&amp;ndash;4 g/day combined to statin therapy decrease elevated serum triglyceride concentrations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The decreased rate of arterial events in association with fish oil intake is probably not due to the triglyceride-lowering effect. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When high doses of fish oils are consumed a possible increase in bleeding tendency should be borne in mind. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Thyroxine Replacement Therapy in Hypothyroidism&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Thyroxine replacement therapy normalizes lipid disorders caused by hypothyroidism (Danese et al., 2000; Chu &amp;amp; Crapo, 2001) &lt;strong&gt;[C]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Follow-up of Drug Therapy&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lipid concentrations should initially be controlled after 1 to 2 months, then after 3 to 6 months if necessary, and thereafter annually. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Make sure that the target lipid levels are reached (see above). With statin therapy this is usually not a problem as long as the drug dosage is appropriately adjusted. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Safety Tests&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Statins&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Serum alanine transaminase (ALT) should be determined 1 to 2 months after the onset of therapy and thereafter usually once a year.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Concentrations greater than twice the upper limit of the reference range are clinically significant. A slight increase in serum ALT concentration is an indication for follow-up, not necessarily for discontinuation of the drug. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If unexplained myalgia should occur, serum creatine kinase should be determined if necessary. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Fibrates&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Serum ALT is determined after 1 to 2 months, and thereafter at 6 to 12 month intervals. If used in combination with statins, ALT should be determined at 3 to 4 month intervals (when combined with a fibrate, the statin dosage should be only half of the normal). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If myalgia occurs serum creatine kinase should always be examined. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Indications for Specialist Consultation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Starting statin or fibrate therapy is contemplated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A lipid disorder is associated with another complicated disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum triglyceride concentration is primarily above 10 mmol/l or remains above 5 mmol/l despite treatments. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Very high plasma cholesterol concentration (above 15 mmol/l) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ischaemic heart disease or xanthomas occur in childhood or in adolescents or young adults. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Related Evidence&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to the original guideline document for related evidence, including Cochrane reviews and other evidence summaries.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classification of the Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Grading the Quality of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Code&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;High&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very unlikely to change confidence in the estimate of effect.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Several high-quality studies with consistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;In special cases: one large, high-quality multi-centre trial &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One high-quality study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Several studies with some limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Very Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Any estimate of effect is very uncertain.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;No direct research evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with very severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group (modified by the EBM Guidelines Editorial Team).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16214597&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999 Jan;69(1):30-42. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9925120&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):187-95. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9974397&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 2. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15007110&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab. 2001 Oct;86(10):4591-9. [96 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11600508&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ. 1997 Jan 11;314(7074):112-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9006469&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006 May 13;332(7550):1115-24. [50 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585050&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006 Jan 4;295(1):74-80. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16391219&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000 Sep;85(9):2993-3001. [64 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10999775&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gardner CD, Kraemer HC. Monounsaturated versus polyunsaturated dietary fat and serum lipids. A meta-analysis. Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1917-27. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7583572&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor  monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995 Jul-Aug;29(7-8):743-59. [114 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8520093&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994 May-Jun;16(3):366-85; discussion 365. [71 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7923304&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Olson BH, Anderson SM, Becker MP, Anderson JW, Hunninghake DB, Jenkins DJ, LaRosa JC, Rippe JM, Roberts DC, Stoy DB, Summerbell CD, Truswell AS, Wolever TM, Morris DH, Fulgoni VL 3rd. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but  not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. J Nutr. 1997 Oct;127(10):1973-80. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9311953&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007 Dec 1;370(9602):1829-39. [25 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18061058&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999 Aug 9-23;159(15):1793-802. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10448784&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7968073&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med. 1996 Dec 15;125(12):990-1000. [72 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8967711&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ. 1998 Apr 18;316(7139):1213-20. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9552999&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Preventing the progress of arterial disease in those already affected (the most important patient group to be treated) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Decreasing the risk of atherosclerotic arterial disease guided by the total risk (combined effect of risk factors) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Adverse Effects of Drug Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See &quot;Major Recommendations&quot; section for specific adverse effects of the various drug classes.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The use of fibrates is contraindicated in patients with severe renal or hepatic dysfunction or diseases of the gallbladder.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Finnish Medical Society Duodecim. Treatment of dyslipidaemias. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp; Sons; 2010 Aug 3&amp;nbsp;[Various]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2001 Apr 4 (revised 2010 Aug 3)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Finnish Medical Society Duodecim - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Finnish Medical Society Duodecim&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Editorial Team of EBM Guidelines&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Primary Authors&lt;/em&gt;: Timo Strandberg; Hannu Vanhanen&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates previous versions:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Finnish Medical Society Duodecim. Treatment of hyperlipidaemia: aims and selection. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp;amp; Sons; 2007 Feb 9 [Various].&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Finnish Medical Society Duodecim. Drug treatment for hyperlipidaemias. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp;amp; Sons; 2008 Jan 3 [Various]. [3 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is included in &quot;EBM Guidelines. Evidence-Based Medicine&quot; available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: &lt;a href=&quot;mailto:info@ebm-guidelines.com&quot;&gt;info@ebm-guidelines.com&lt;/a&gt;; Web site: &lt;a href=&quot;http://www.ebm-guidelines.com&quot; title=&quot;EBM Guidelines Web site&quot;&gt;www.ebm-guidelines.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on March 16, 2001. The information was verified by the guideline developer as of June 15, 2001. The summary was updated by ECRI on August 17, 2001, December 9, 2002, December 29, 2003, and July 15, 2004. This summary was updated by ECRI on March 4, 2005, following the release of a public health advisory from the U.S. Food and Drug Administration regarding the use of revised labeling for the drug Crestor (rosuvastatin calcium). This summary was updated by ECRI Institute on September 25, 2008 and May 6, 2011. This summary was updated by ECRI Institute on November 22, 2011 following the U.S. Food and Drug Administration (FDA) advisory on Trilipix (fenofibric acid). This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
